Director Johnson Karen Marie bought 36.2K shares of Oncology Institute at $1.04 amid 7-insider buy cluster; company unprofitable despite 21.3% revenue growth.
Director Johnson Karen Marie purchased 36,224 shares at $1.04 per share on 2025-03-26, expanding her holdings from 167.2K to 203.4K shares (+21.7%). The transaction occurs within a 7-insider buy cluster over 14 days, suggesting coordinated conviction-testing among multiple insiders at a single company. Oncology Institute's fundamentals present a mixed signal: while annual revenue growth reached +21.3%, the company reported a net loss of $-16.1M against revenue of $99.9M, indicating persistent unprofitability. The stock's price context adds complexity—currently at $1.14 versus a 52-week range of $0.13–$1.84, it has recovered +19.2% over 30 days and +260.2% over 90 days from depressed levels, yet remains -38.0% below its 52-week high. The cluster buy pattern at recovery prices warrants investor scrutiny of whether insiders view the operational trajectory as inflection or the price recovery as temporary opportunity.